We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 6
Most popular |Most recent


Delaware Found to be Improper Venue for ANDA Suit

USA - October 31 2018 The District of Delaware dismissed a Hatch-Waxman Act ANDA lawsuit that Bristol-Myers Squibb had filed against Mylan Pharmaceuticals, finding that...


Federal Circuit En Banc Denials Confirm Fact Issues Implicated by Patent-Eligibility Inquiry

USA - June 12 2018 The United States Court of Appeals for the Federal Circuit refused rehearing en banc of two significant decisions regarding patent-eligibility under...

Michael A. Fisher.


USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent

USA - April 13 2018 Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients...


Federal Circuit Decisions Raise Bar for Invalidating Patents on Section 101 Grounds Before Trial

USA - February 21 2018 Two recent Federal Circuit decisions in the U.S., both penned by Judge Moore, significantly raise the bar for accused infringers seeking to invalidate...


Federal Circuit Clarifies the “Reasonable Expectation of Success” Required in Hatch-Waxman Obviousness Challenges

USA - January 13 2018 The U.S. Federal Circuit recently clarified the standard that patent challengers must satisfy when attempting to invalidate patented inventions...

Joe Gribbin.